Advances in molecular targeted agents have prolonged survival, especially in patients with lung cancer harboring epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangement, and in patients with breast cancer harboring human epidermal growth factor receptor 2 (HER2) amplification. Here, ALK is linked to breast carcinoma.